Denosumab can be used as an alternative to zoledronic acid in the treatment of bone metastases in prostate cancer, but its use is not yet supported in prevention, a prospective trial reported in the Lancet suggests.
Randomising almost 1,500 patients with non-metastatic castration-resistant prostate cancer to either denosumab or placebo, the researchers found the drug reduced risk of bone-metastases by 15% and delayed time to detection of metastases by 4.2 months.
However, they did not find any effect of denosumab on survival.
In an accompanying piece, an editorialist wrote that the findings “support the concept that targeting of bone metastases in prostate cancer will be therapeutically beneficial.”
But, he continued, “because the duration of benefit is similar in both the pre-metastatic and...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.